Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A nanovaccine targeting cancer stem cells and bulk cancer cells reduces post-surgical tumor relapse [RIP-Seq]

ABSTRACT: Residual cancer stem-like cells (CSCs) can cause tumor recurrence within a narrow margin around the initial tumour resection lesion, increasing post-surgical risk of relapse and incurability. Currently there are no efficient strategies for tracking and eradicating CSCs. Here we propose a nanovaccine strategy, NICER, based on a nanovesicle system integrating CSC-specific antigen (CSA) display and epigenetic nano-regulator (ENR)-encapsulation with a dendritic cell (DC)-targeting aptamer, to simultaneously eradicate CSCs and bulk tumor cells. Specifically, nanovesicles derived from aldehyde dehydrogenase-overexpressing tumors could serve as integrated antigens carrying both CSA and tumor associated antigen (TAA). ENR targeting YTH N6-methyladenosine RNA binding protein 1 could restrict DC lysosomal protease activity to modulate the effective cross-presentation of integrated antigens via major histocompatibility complex class I (MHC I) for immune responses. Overall, NICER represents a broad-spectrum vaccine approach against both CSCs and bulk tumors that can significantly inhibit postoperative cancer recurrence and metastasis, prolonging survival rates.

ORGANISM(S): Mus musculus

PROVIDER: GSE293556 | GEO | 2026/03/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A nanovaccine targeting cancer stem cells and bulk cancer cells reduces post-surgical tumor relapse [meRIP-seq]

Project description:Residual cancer stem-like cells (CSCs) can cause tumor recurrence within a narrow margin around the initial tumour resection lesion, increasing post-surgical risk of relapse and incurability. Currently there are no efficient strategies for tracking and eradicating CSCs. Here we propose a nanovaccine strategy, NICER, based on a nanovesicle system integrating CSC-specific antigen (CSA) display and epigenetic nano-regulator (ENR)-encapsulation with a dendritic cell (DC)-targeting aptamer, to simultaneously eradicate CSCs and bulk tumor cells. Specifically, nanovesicles derived from aldehyde dehydrogenase-overexpressing tumors could serve as integrated antigens carrying both CSA and tumor associated antigen (TAA). ENR targeting YTH N6-methyladenosine RNA binding protein 1 could restrict DC lysosomal protease activity to modulate the effective cross-presentation of integrated antigens via major histocompatibility complex class I (MHC I) for immune responses. Overall, NICER represents a broad-spectrum vaccine approach against both CSCs and bulk tumors that can significantly inhibit postoperative cancer recurrence and metastasis, prolonging survival rates.

2026-03-21 | GSE293557 | GEO

A multi-adjuvant nanovaccine platform based on targeted delivery of specific antigens for cancer immunotherapy

Project description:Cance vaccines have become a milestone in immunotherapy, but inadequate activation rate of antigen presenting cells (APCs) and low delivery efficiency of specific antigen have widely limited their clinical application. Here we design an engineered vaccine platform based on targeted delivery of specific antigens to activated APCs. This vaccine platform is implemented by loading stimulator of interferon genes agonist and tumor lysate protein with calcium phosphate as adjuvants, and coating the surface with mannose-modified liposomes. By loading different types of tumor antigen proteins, this nanovaccine platform successfully achieves tumor immunotherapy in breast and colon cancer bearing mice. In addition, personalized nanovaccine prepared from surgically removed tumor lysate proteins also significantly suppresses postsurgical distant tumor. Through the design of nanovaccine platform, we provide an efficient multi-adjuvant delivery platform for multiple types of tumor antigens, and also offer more ideas for personalized vaccine immunization. This nanovaccine platform has great prospects for transformation due to the designability and simplicity for the preparation.

2024-05-14 | GSE267162 | GEO

Abernathy2016 - glioblastoma treatment

Project description:The paper describes a model of glioblastoma. Created by COPASI 4.25 (Build 207) This model is described in the article: Modeling the Treatment of Glioblastoma Multiforme and Cancer Stem Cells with Ordinary Differential Equations Kristen Abernathy and Jeremy Burke BMC Computational and Mathematical Methods in Medicine Volume 2016, Article ID 1239861, 11 pages Abstract: Despite improvements in cancer therapy and treatments, tumor recurrence is a common event in cancer patients. One explanation of recurrence is that cancer therapy focuses on treatment of tumor cells and does not eradicate cancer stem cells (CSCs). CSCs are postulated to behave similar to normal stem cells in that their role is to maintain homeostasis. That is, when the population of tumor cells is reduced or depleted by treatment, CSCs will repopulate the tumor, causing recurrence. In this paper, we study the application of the CSC Hypothesis to the treatment of glioblastoma multiforme by immunotherapy. We extend the work of Kogan et al. (2008) to incorporate the dynamics of CSCs, prove the existence of a recurrence state, and provide an analysis of possible cancerous states and their dependence on treatment levels. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

2024-09-02 | BIOMD0000000757 | BioModels

Proteins and Molecular Pathways Relevant for Stemness Properties of Tumor-Initiating Pancreatic Cancer Stem Cells Recognized by Differential Proteome-, Gene Expression-, and Functional Analysis

Project description:Cancer stem cells (CSCs), a small subset of the tumor bulk with highly malignant properties, are deemed responsible for tumor initiation, growth, metastasis, and relapse. In order to reveal molecular markers and determinants of stemness properties, pancreatic CSCs were enriched in three-dimensional spheroid cultures of two highly metastatic pancreatic cancer cell lines (L3.6sl and L3.6pl) and compared to bulk tumor cells using differential proteomics (PTX). We identified about 400 putative target proteins with significantly different expression in pancreatic CSCs and bulk tumor cells. By combining the unbiased PTX with gene expression analysis using quantitative polymerase chain reaction (qPCR) we nominated the two calcium binding proteins S100A8 (MRP8) and S100A9 (MRP14), as well as galactin-3-binding protein LGALS3BP (MAC-2-BP) as putative determinants of pancreatic CSCs. In silico pathway analysis followed by candidate-based RNA interference mediated functional analysis revealed a critical role of S100A8, S100A9, and LGALS3BP as molecular determinants of CSC proliferation, migration and in vivo tumor initiation. Our study highlights the power of combining unbiased proteomics with focused gene expression and functional analyses for the identification of key regulators of CSCs, an approach that warrants further application to identify CSCs proteins amenable to drug targeting.

2020-06-25 | PXD018585 | Pride

Integrating antigen capturing nanoparticles and type 1 conventional dendritic cell therapy for in situ cancer immunization

Project description:Eliciting a robust immune response against tumors is often hampered by the inadequate presence of effective antigen presenting cells and their suboptimal ability to present antigens within the immunosuppressive tumor microenvironment. Here, we report a cascade antigen relay strategy integrating antigen capturing nanoparticles (AC-NPs) and migratory type 1 conventional dendritic cells (cDC1s), named Antigen Capturing nanoparticle Transformed Dendritic Cell therapy (ACT-DC), to facilitate in situ immunization. AC-NPs are engineered to capture antigens directly from the tumor and facilitate their delivery to adoptively transferred migratory cDC1s, enhancing antigen presentation to the lymph nodes and reshaping the tumor microenvironment. Our findings suggest that ACT-DC improves in situ antigen collection, triggers a robust systemic immune response without the need for exogenous antigens, and transforms the tumor environment into a more “immune-hot” state. In multiple tumor models including colon cancer, melanoma, and glioma, ACT-DC in combination with immune checkpoint inhibitors eliminates primary tumors in 50-100% of treated mice and effectively rejects two separate tumor rechallenges. Collectively, ACT-DC could provide a broadly effective approach for in situ cancer immunization and tumor microenvironment modulation.

2025-04-03 | PXD062399 | Pride

GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy

Project description:Recent studies revealed that treatment resistant cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) can be targeted by cytotoxic T lymphocytes (CTLs). CTLs recognize antigenic peptide derived from tumor-associated antigens (TAAs), thus identification of tumor-associated antigens (TAAs) expressed in CSCs/CICs is essential. Human leucocyte antigen (HLA) ligandome analysis using mass spectrometry enables analysis of naturally expressed antigenic peptides; however, HLA ligandome analysis requires large scale of sample and it is challenging for CSCs/CICs. In this study, we established novel bladder CSC/CIC model from a bladder cancer cell line UM-UC-3 cells using ALDEFLUOR assay. CSCs/CICs were isolated as aldehyde dehydrogenase (ALDH) high cells and several ALDHhigh clone cells were established. ALDHhigh clone cells were enriched with CSCs/CICs by sphere formation and tumorigenicity in immune deficient mouse. HLA ligandome analysis and gene expression (CAGE) using ALDHhigh clone cells revealed distinctive antigenic peptide repertoire in bladder CSCs/CICs, and we identified GRIK2 derived antigenic peptide is specifically expressed in CSCs/CICs. GRIK2 peptide-specific CTL clone recognized GRIK2-overexpressed UM-UC-3 cells and ALDHhigh clone cells indicating that GRIK2 peptide can be a novel target for bladder CSCs/CICs-targeting immunotherapy.

2021-10-01 | GSE166947 | GEO

Transcriptome analysis of cancer stem cells in triple-negative cancer

Project description:Cancer stem cells (CSCs) are thought to be the source of drug resistance, metastasis and tumor recurrence in cancer treatment. The goal of this study was to identify the differentially expressed genes between CSCs and non-stem cancer cells (NSCs). RNA sequencing and bioinformatic analyses revealed that 963 genes are differentially expressed (FDR < 0.4) in TNBC CSCs as compared to NSCs.

2024-08-18 | GSE119245 | GEO

miRNA Expression data from CD133+CD15+ chordoma cells (Chordoma Cance Stem Cells) and CD133-CD15- chordoma cells

Project description:Chordoma is a rare, resistant bone tumor thought to be arised from remnants of embryonic notochord. Cancer stem cells (CSCs) are associated with tumorigenesis, recurrence and resistance in cancers. Here, we used miRNA and mRNA transcriptome analysis to discover novel genes and networks in chordoma CSCs

2019-04-15 | GSE109943 | GEO

Comparison of gene expression profilling between iPS vs SSEA-1 positive or SSEA-1/3 negative sorted N417 cell line

Project description:To prove that hypoxia generates Cancer stem cells (CSCs) from non-CSCs, we needed to separate out already existing tumorigenic cells from the cell population. To identify CSCs, we used ES cell-specific cell surface antigens (SSEA-1, -3, -4, and Tra1-81) on the assumption that the immature cell fraction would be rich in CSCs. We analyzed the expression levels of such embryonic antigens and stemness genes in cells exposed to hypoxia. iPS (253G1), SSEA-1 positive-N417 3 of SSEA-1/3 double negative-N417, each condition is represented by 3 biological replicates

2012-09-13 | E-GEOD-40842 | biostudies-arrayexpress

Expression data from LNCaP cells

Project description:Prostate Cancer Stem Cells (CSCs) are considered one of the main reasons the tumor recurrence after chemotherapy. Here we employed a chemoresistant xenograft prostate cancer model in NOD/SCID mice and found CD54 is a reliable new marker for prostate CSCs. Gene expression profile were utilized to analyze stemness-related genes in cancer stem cells.

2016-02-23 | GSE78196 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data